APA (7th ed.) Citation

Fink, M., Vittrup, A. S., Bastholt, L., Svane, I. M., Donia, M., Luczak, A. A., . . . Schmidt, H. (2021). Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study. Cancers, 13(21), 5550. https://doi.org/10.3390/cancers13215550

Chicago Style (17th ed.) Citation

Fink, Morten, et al. "Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study." Cancers 13, no. 21 (2021): 5550. https://doi.org/10.3390/cancers13215550.

MLA (9th ed.) Citation

Fink, Morten, et al. "Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study." Cancers, vol. 13, no. 21, 2021, p. 5550, https://doi.org/10.3390/cancers13215550.